株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多系統萎縮症(MSA、シャイ・ドレーガー症候群、多系統変性症):パイプライン製品の分析

Multiple System Atrophy - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 410989
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.00円で換算しております。
Back to Top
多系統萎縮症(MSA、シャイ・ドレーガー症候群、多系統変性症):パイプライン製品の分析 Multiple System Atrophy - Pipeline Review, H1 2017
出版日: 2017年06月13日 ページ情報: 英文 33 Pages
概要

多系統萎縮症(MSA) 、またはシャイ・ドレーガー症候群とは、血圧や心拍、膀胱機能、消化といった、体の不随意機能を損なう神経変性疾患です。症状は、筋肉の硬直、 動作の緩慢、震え、構音障害、嚥下障害、便秘、失禁、不整脈などです。治療は抗パーキンソン病薬で症状の緩和を目的とします。

当レポートでは、多系統萎縮症(MSA、シャイ・ドレーガー症候群、多系統変性症)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを提供しています。

イントロダクション

  • 調査範囲

多系統萎縮症(MSA、シャイ・ドレーガー症候群、多系統変性症) 概要

治療薬の開発

  • パイプライン製品;概要

企業で開発中の治療薬

パイプライン製品の概況

  • 治験段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬開発に従事している企業

  • AFFiRiS AG
  • AstraZeneca Plc
  • Corestem Inc
  • MitoDys Therapeutics Ltd
  • Modag GmbH
  • Neuropore Therapies Inc
  • Prana Biotechnology Ltd

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Anle-138b
  • AZD-3241
  • CS-10BR05
  • NPT-20011
  • PBT-434
  • PD-01
  • PD-03
  • 神経変性疾患向け小分子

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9414IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy - Pipeline Review, H1 2017, provides an overview of the Multiple System Atrophy (Central Nervous System) pipeline landscape.

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple System Atrophy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 1, 3 and 1 respectively.

Multiple System Atrophy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Multiple System Atrophy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Multiple System Atrophy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Overview
    • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Companies Involved in Therapeutics Development
    • AFFiRiS AG
    • Corestem Inc
    • Neuropore Therapies Inc
    • Prana Biotechnology Ltd
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drug Profiles
    • Anle-138b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-10BR05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ENT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-20011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBT-434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Neurodegenerative Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by AFFiRiS AG, H1 2017
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Corestem Inc, H1 2017
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Neuropore Therapies Inc, H1 2017
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline by Prana Biotechnology Ltd, H1 2017
  • Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top